“My cough was really so deep that it felt like I broke my ribs, and my ribs became so cramped that I couldn’t even twist [my body].”

Voice of the Patient Report: “Idiopathic Pulmonary Fibrosis”, March 2015.

“My cough was really so deep that it felt like I broke my ribs, and my ribs became so cramped that I couldn’t even twist [my body].”

Voice of the Patient Report: “Idiopathic Pulmonary Fibrosis”, March 2015.

Haduvio and Chronic Cough

Chronic cough impacts up to 10% of the adult population and has physical, psychological, and social impacts on patients’ lives. We are investigating the use of Haduvio for idiopathic pulmonary fibrosis (IPF) patients with chronic cough and refractory chronic cough (RCC) patients. The chronic cough these patients experience is highly disruptive and accompanied by a wide range of complications, which causes a significant burden on patients, caregivers, and healthcare systems. Currently, there are no approved therapies in the U.S. for these conditions. 

The cause of chronic cough is believed to be the result of a hypersensitivity disorder in the central and peripheral nerves. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that we believe play a key role in controlling cough hypersensitivity. In a previous Phase 2 study (CANAL), Haduvio reduced daytime cough frequency by 75% in IPF patients. The safety results of the CANAL trial were generally consistent with the known safety profile of Haduvio from previous trials. To build upon this positive data, we are advancing future clinical development on chronic cough conditions, including IPF and RCC.